Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck cancer, excluding thyroid

859 - A New Classification for Nasopharyngeal Carcinoma


09 Sep 2017


Head and neck cancer, excluding thyroid


Cancers in Adolescents and Young Adults (AYA);  Staging Procedures (not Imaging);  Head and Neck Cancers


Hung Chun Cheng


Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374


H.C.S. Cheng1, C. Horng2

Author affiliations

  • 1 Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center, 112 - Taipei/TW
  • 2 Clinical Research, Koo Foundation Sun Yat-Sen Cancer Center, 112 - Taipei/TW


Abstract 859


This study is to develop and validate a new classification for nasopharyngeal carcinoma (NPC).


Fifteen hundred and twenty-eight (1528) newly diagnosed NPC patients treated between 1995 and 2010 were included in this study. Seven hundred and one patients (n = 701) were treated with 3D conformal radiotherapy (3D-RT) and 827 patients were treated with IMRT. Cox proportional hazards model was used to select the significant split node to partition patients into the different risk group. Recursive partitioning analysis derived a new classification in patients treated with 3D-RT objectively. This new staging system was then validated in patients treated with IMRT.


The median follow-up interval was 84.6 months (ranging 2-175 months). According to the 7th AJCC staging system, the stage I patients showed a 5-year overall survival (OS) rate of 93.0%, stage II of 94.5%, stage III of 87.5%, stage IVA of 71.5%, stage IVB of 61.3%, and stage IVC of 5.8% (p 


We propose a new staging system for NPC, which distributes more patients in the early stage.Table:

1054PD Patient Distribution According to Chinese 2008 and the 7th AJCC staging systems

StageChinese 2008 staging2010 AJCC stagingCurrent proposal
Stage I2.3%2.3%42.9%
Stage II11.0%23.7%21.9%
Stage III39.4%49.1%30.0%
Stage IV47.3%24.9%5.2%

Clinical trial identification

Not applicable

Legal entity responsible for the study



Koo Foundation Sun Yat-Sen Cancer Center


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.